Elranatamab is a bispecific antibody approved by the FDA in August 2023 that offers a new treatment option for patients with multiple myeloma. Similar to teclistamab (Tecvayli), elranatamab works by targeting a protein called B-cell maturation antigen (BCMA) found on the surface of myeloma cells. This targeted approach helps recruit the body's own immune system to attack and destroy these cancer cells.

Indication (Who Can Receive It)

Elranatamab is intended for adults with multiple myeloma who have had at least one immunomodulatory agent (like lenalidomide or pomalidomide), one proteasome inhibitor (like bortezomib or carfilzomib), and one anti-CD38 monoclonal antibody (like daratumumab or isatuximab).

Administration

Elranatamab is administered subcutaneously (via injection). The initial treatment involves a specific dosing schedule with "step-up" priming doses, followed by regular infusions every 2 weeks. The exact duration of treatment depends on individual patient tolerance and response.

Response

The approval was based on the results of the Phase 2 trial (MagnetisMM-3), where elranatamab produced an overall response rate of 58%, with 26% of patients achieving a complete remission. Within this trial, 33% of patients who received a previous BCMA-directed therapy responded to elranatamab.

Side Effects and Adverse Events

Some of the most common side effects reported in elranatamab’s clinical trials include: CRS in up to 58% of patients, with most cases being manageable; low levels of a specific type of white blood cell (called a neutrophil) that is important for fighting infections in 48% of patients; and neurological toxicities in 59% of patients, which can include confusion, dizziness, and difficulty walking or speaking.

For more information on elranatamab, visit elrexfio.com